The Indian government has begun collecting feedback from pharmaceutical exporters to identify regulatory and market-access hurdles affecting shipments to eight Asian countries, as part of efforts to strengthen the country’s pharma exports and improve trade competitiveness in the region.
Industry sources said the exercise is aimed at understanding non-tariff barriers, product registration delays, pricing controls, quality certification requirements and customs-related issues faced by Indian drug makers in overseas markets. The inputs will help the government formulate strategies to ease export bottlenecks and expand India’s pharmaceutical footprint across Asia.
The initiative comes amid rising global demand for affordable generic medicines and increasing competition in international markets. Officials are engaging with exporters, industry associations and trade bodies to gather detailed information on challenges affecting product approvals, compliance procedures and supply chain operations in destination countries.
India is one of the world’s largest suppliers of generic medicines and vaccines, with pharmaceutical exports playing a key role in the country’s merchandise trade. Industry participants said resolving regulatory hurdles and improving market access could help Indian companies increase exports of formulations, active pharmaceutical ingredients (APIs) and specialty drugs across emerging Asian economies.
The government has been taking multiple steps to support the pharmaceutical sector through export promotion initiatives, trade negotiations and regulatory cooperation with partner countries. Exporters expect the latest review to help streamline procedures and strengthen India’s position in regional healthcare supply chains.